Anaplerotic nutrient stress drives synergy of angiogenesis inhibitors with therapeutics targeting tumor metabolism
Preprint
- 21 June 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Tumor angiogenesis is a cancer hallmark, and its therapeutic inhibition has provided meaningful, albeit limited, clinical benefit. While anti-angiogenesis inhibitors deprive the tumor of oxygen and essential nutrients, cancer cells activate metabolic adaptations to diminish therapeutic response. Despite these adaptations, angiogenesis inhibition incurs extensive metabolic stress, prompting us to consider such metabolic stress as an induced vulnerability to therapies targeting cancer metabolism. Metabolomic profiling of angiogenesis-inhibited intracranial xenografts showed universal decrease in tricarboxylic acid cycle intermediates, corroborating a state of anaplerotic nutrient deficit or stress. Accordingly, we show strong synergy between angiogenesis inhibitors (Avastin, Tivozanib) and inhibitors of glycolysis or oxidative phosphorylation through exacerbation of anaplerotic nutrient stress in intracranial orthotopic xenografted gliomas. Our findings were recapitulated in GBM xenografts that do not have genetically predisposed metabolic vulnerabilities at baseline. Thus, our findings cement the central importance of the tricarboxylic acid cycle as the nexus of metabolic vulnerabilities and suggest clinical path hypothesis combining angiogenesis inhibitors with pharmacological cancer interventions targeting tumor metabolism for GBM tumors.Keywords
All Related Versions
This publication has 56 references indexed in Scilit:
- Quantification of Phosphonate Drugs by 1H–31P HSQC Shows That Rats Are Better Models of Primate Drug Exposure than MiceAnalytical Chemistry, 2022
- Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative PhosphorylationCell Reports, 2019
- Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancerEuropean Journal of Medicinal Chemistry, 2017
- Near-optimal probabilistic RNA-seq quantificationNature Biotechnology, 2016
- The Molecular Signatures Database Hallmark Gene Set CollectionCell Systems, 2015
- Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomasActa Neuropathologica, 2014
- 3D Slicer as an image computing platform for the Quantitative Imaging NetworkMagnetic Resonance Imaging, 2012
- Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic DrugsCancer Cell, 2012
- Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetaseBritish Journal of Cancer, 2011
- Treatment with bevacizumab and irinotecan for recurrent high‐grade glial tumorsCancer, 2008